Cure Alzheimer's Fund Cure Alzheimer's Fund

Gary Landreth, Ph.D.

AD projects in Dr. Landreth’s laboratory are directed at understanding how the beta-amyloid peptides are normally cleared from the brain and the roles of inflammation in AD pathogenesis. The lab is also engaged in identification and validation of new therapeutic agents for the treatment of AD.  Dr. Landreth received his B.A. from the University of Kansas, and his Ph.D. from the University of Michigan.

Related Research:

Mechanisms of Retinoid X Receptor-Mediated Abeta Clearance in Alzheimers’ Disease David Holtzman Gary Landreth 2011-11-11 Effect of Bexarotene on Abeta in APP Tg Mice Expressing ApoE3 and ApoE4 David Holtzman Gary Landreth 2011-11-11

Funded Research

These projects were made possible from Cure Alzheimer's Fund support.

Project Description Researchers Funding
Mechanisms of Retinoid X Receptor-Mediated Abeta Clearance in Alzheimers’ Disease 2011

$100,000
Effect of Bexarotene on Abeta in APP Tg Mice Expressing ApoE3 and ApoE4 2011

$100,000

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.

Claes, C., England, W. E., Danhash, E. P., Kiani Shabestari, S., Jairaman, A., Chadarevian, J. P., Hasselmann, J., Tsai, A. P., Coburn, M. A., Sanchez, J., Lim, T. E., Hidalgo, J. L. S., Tu, C., Cahalan, M. D., Lamb, B. T., Landreth, G. E., Spitale, R. C., Blurton-Jones, M., & Davtyan, H. The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer’s disease mouse model, Alzheimer's & Dementia, February 9, 2022, Read More

Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., Brunden, K. R., Wilson, D. A., & Landreth, G. E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models, Science, March 23, 2012, Read More

Back to Our Researchers